Summaries of current peer-reviewed research.
Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA-approved as Mounjaro and Zepbound for prescription human use. This research guide covers its mechanism, SURPASS/SURMOUNT trial data, tolerability findings including the ongoing SURMOUNT-MMO outcomes trial, and how it compares to semaglutide. Research Use Only.
Evidence & Research Status FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) — not for human consumption
Evidence & Research Status Evidence LevelEmerging Human Research FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) —
Evidence & Research Status FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) — not for human consumption
Evidence & Research Status FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) — not for human consumption
Evidence & Research Status Evidence LevelExtensive Human Clinical Data FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO)
Evidence & Research Status Evidence LevelExtensive Human Clinical Data FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO)
Evidence & Research Status FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) — not for human consumption
Evidence & Research Status Evidence LevelExtensive Human Clinical Data FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO)
Evidence & Research Status Evidence LevelEmerging Human Research FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) —
Discount Applied Successfully!
Your savings have been added to the cart.